COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Risk Factors of Porphyria Cutanea Tarda (PCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00213772
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : September 21, 2005
Information provided by:
University Hospital, Strasbourg, France

Brief Summary:

Comparison of patients with documented PCT and HCV infection, documented PCT without HCV, HCV infection without PCT and controls without HCV or PCT.

Single blood + urine sample uptake to investigate : mutations in HFE gene, uroporphyrinogen decarboxylase activity, HCV genotye, history of disease.

Condition or disease
Porphyria Cutanea Tarda

Layout table for study information
Study Type : Observational
Enrollment : 280 participants
Observational Model: Case Control
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: “Factors Associated With Porphyria Cutanea Tarda in Patients Infected With Hepatitis C Virus”
Study Start Date : May 1999

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Porphyria cutanea tarda /HCV negative Porphyria cutanea tarda/ HCV positive HCV positive HCV negative controls

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00213772

Sponsors and Collaborators
University Hospital, Strasbourg, France
Layout table for investigator information
Principal Investigator: Bernard Cribier, MD Hopitaux Universitaires de Strasbourg
Principal Investigator: O. Chosidow, MD Hopital Pitié-Salpétrière / Paris
Principal Investigator: M. Bagot, MD Hopital Henri Mondor / CHU Créteil
Principal Investigator: J.P Lacour, MD Hopital de l'Archet / CHU Nice

Layout table for additonal information Identifier: NCT00213772    
Other Study ID Numbers: 2030
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: September 21, 2005
Last Verified: September 2005
Keywords provided by University Hospital, Strasbourg, France:
Porphyria cutanea tarda
hepatitis C
Additional relevant MeSH terms:
Layout table for MeSH terms
Porphyria Cutanea Tarda
Porphyrias, Hepatic
Porphyria, Erythropoietic
Metabolic Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Liver Diseases
Digestive System Diseases